Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Shionogi Facing Xofluza Supply Crunch as Flu Season Gets into Full Swing
January 21, 2019
-
BUSINESS Mitsubishi Tanabe Staffers Tapping New Support System to Balance Work and Infertility, Medical Treatment
January 18, 2019
-
REGULATORY PMDA to Specify Target Overall Review Period for Regenerative Medicine Products: FY2019-2023 Plan
January 17, 2019
-
REGULATORY MHLW Won’t Necessarily Push March Announcement of New Drug Prices: Bureau Head
January 16, 2019
-
BUSINESS Japan Pharma Market Sags 2% in April-December as Pricing Overhaul Weighs: Encise
January 15, 2019
-
REGULATORY PMDA to Raise Fees and Expand Workforce to Boost Review and Safety Measures, GMP Inspection
January 15, 2019
-
COMMENTARY 2019 Likely to Herald Burst of “Regenerative Medicine” Approvals
January 11, 2019
-
REGULATORY MHLW to Revise Biosimilar Guidelines to Increase Efficiency in Development, Review; Final Draft Expected in FY2019
January 10, 2019
-
REGULATORY MHLW Approves Amgen/Astellas’ Evenity, Gilead Sciences’ Epclusa and More
January 9, 2019
-
BUSINESS Takeda Completes £46 Billion Shire Acquisition
January 8, 2019
-
REGULATORY MHLW to Follow Up on Drug Makers’ Efforts to Observe New Detailing Guidelines
January 7, 2019
-
BUSINESS Can Daiichi Sankyo Take Big Leap in Oncology with 3 FDA Nods in FY2019?
January 4, 2019
-
BUSINESS Reata Developing Sakigake Designated DKD Drug for Alport Syndrome in Japan
December 28, 2018
-
BUSINESS Biogen Japan Set to “Make Impossible Possible” in Next 5 Years, Double Neuroscience Pipeline
December 27, 2018
-
TRENDS Top 10 PHARMA JAPAN Stories in 2018
December 26, 2018
-
BUSINESS Some Drug Makers Stop Distributing 2019 Calendars with Revised JPMA Code of Practice Set to Take Effect in January
December 25, 2018
-
REGULATORY MHLW OKs Add’l Indications for Keytruda, Tecentriq, Hemlibra, and More
December 25, 2018
-
REGULATORY After Settling on October 2019 Re-Pricing, When Will Govt Reveal New Drug Prices?
December 21, 2018
-
REGULATORY PhRMA, EFPIA Pitch Enhanced Appraisal Model for Japan HTA Plan; Chuikyo Reps Acknowledge ICER Limitations
December 20, 2018
-
REGULATORY Govt to Pare Drug Prices by 2.4% in October 2019 Ad-Hoc Re-Pricing
December 19, 2018
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…